Genetically modified isopropylmalate isomerase enzyme complexes (e.g., LeuCD enzyme complexes), microbial organisms including genetically modified isopropylmalate isomerase enzyme complexes (e.g., LeuCD), and processes for preparing C7-C11 2-ketoacids with genetically modified isopropylmalate isomerase enzyme complexes (e.g., LeuCD). The genetically modified isopropylmalate isomerase enzyme complexes (e.g., LeuCD enzyme complexes), microbial organisms, and processes for preparing C7-C11 2-ketoacids can be used to produce C6-C10 aldehydes, alkanes, alcohols, and carboxylic acids, both in vivo and in vitro.

The present invention relates to polymer particles and uses thereof. In particular the present invention relates to functionalized polymer particles, processes of production and uses thereof in the diagnosis, treatment or prevention of tuberculosis.

Methods for the improved acylation of chemical substrates using LovD acyltransferases, thioesters having acyl groups, and (i) thiol scavengers and/or (ii) precipitating agents are presented. An improved method for the production of simvastatin using (i) activated charcoal as a thiol scavenger and/or (ii) ammonium hydroxide as a precipitating agent is also presented.

The present invention relates to the field of antimicrobial agents active against Staphylococcus aureus bacteria. In particular, the present invention relates to polypeptides comprising the CHAP domain of LysK endolysin, the M23 endopeptidase domain of lysostaphin, the cell wall binding domain (CBD) of ALE-1, and a further peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a hydrophobic peptide, a sushi peptide and a defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells, compositions and devices. Finally, the present invention relates to applications of the inventive polypeptides, in particular in the pharmaceutical field.

A method of producing lipids, containing the steps of: culturing a transformant in which the expression of a gene encoding the following protein (A) or (B) is enhanced, and producing fatty acids or lipids containing these fatty acids as components: (A) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1; and (B) a protein consisting of an amino acid sequence having 44% or more identity with the amino acid sequence of the protein (A), and having acyltransferase activity.

A method for producing natural rubber by using a recombinant microorganism is disclosed, the method comprising: (a) manufacturing an expression vector capable of expressing a gene encoding a cis-prenyltransferase, which is a guayule-derived natural rubber synthetase represented by the amino acid sequence of SEQ ID NO: 2 or a Hevea brasiliensis-derived natural rubber synthetase represented by the amino acid sequence of SEQ ID NO: 6, and an expression vector capable of expressing a gene coding for a natural rubber precursor synthetase; (b) transforming a host microorganism with the expression vector; (c) culturing the transformed host microorganism; and (d) separating natural rubber from the cultured transformed host microorganism. The natural rubber obtained by the method has a white powder form identical to that of natural rubber, and shows an FT-IR spectrum pattern extremely similar to that of natural rubber.

The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.

The present invention relates to methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.

The disclosure provides genetically engineered microorganisms and methods for improved biological production of ethylene glycol and precursors of ethylene glycol. The microorganism of the disclosure produces ethylene glycol or a precursor of ethylene glycol through one or more of 5,10-methylenetetrahydrofolate, oxaloacetate, citrate, malate, and glycine. The disclosure further provides compositions comprising ethylene glycol or polymers of ethylene glycol such as polyethylene terephthalate.

This disclosure provides a genetically-modified bacterium from the genus Pseudomonas that produces itaconate or trans-aconitate. The disclosure further provides methods for producing itaconate or trans-aconitate using a genetically-modified bacterium from the genus Pseudomonas.